Shares
Creating value with biosimilars
Through our biosimilar development projects, Formycon creates not only highly effective, more affordable biologic drugs for patients but also long-term value for its investors. Biosimilars are a new class of medicines with a very promising future, and our product candidates are targeted at multi-billion-dollar markets.
Formycon AG share chart
Shareholder structure
■ 26,7% ATHOS KG
■ 14,9% Wendeln & Cie. KG
■ 6,7% Active Ownership Corporations S.á.r.l
■ 5,5% DSP Beteiligungsgesellschaft GmbH & Co. KG
■ 6,5% Founders and Management
■ 39,7% Free Float
Legal form
German stock corporation (Aktiengesellschaft)
Initial exchange listing
December 20, 2010
ISIN
DE000A1EWVY8
WKN
A1EWVY
Exchange and market segment
Frankfurt Stock Exchange “Scale” Segment (Open Market)
Share type
Bearer shares without par value
Registered capital
EUR 16,038,775.00
Shares outstanding
16,038,775 bearer shares
Capital Market Partner
Wolfgang Steubing AG
Designated Sponsors
Wolfgang Steubing AG
mwb fairtrade Wertpapierhandelsbank AG
as of March 2023